Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to the combination of alcohol (ethanol) and perampanel. Alcohol is a central nervous system depressant commonly consumed as a recreational beverage. Perampanel is an oral antiepileptic drug used primarily for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures. Perampanel acts as a selective, non-competitive antagonist of the AMPA receptor, thereby reducing abnormal neuronal excitation in the brain[3][4][6]. The combination of these two substances is clinically significant because co-administration can increase central nervous system depression and significantly worsen psychiatric side effects such as mood changes and increased anger[1][2][5][8]. Patients taking perampanel are advised to avoid or limit alcohol consumption due to additive or supra-additive impairment in cognition, vigilance, alertness, and increased risk for behavioral adverse reactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alcohol + perampanel.